Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oramed Pharmaceuticals (ORMP) Net Margin (2022 - 2025)

Oramed Pharmaceuticals' Net Margin history spans 4 years, with the latest figure at 382.1% for Q1 2025.

  • For Q1 2025, Net Margin fell 12298.0% year-over-year to 382.1%; the TTM value through Dec 2025 reached 6346.35%, changed N/A, while the annual FY2025 figure was 3200.8%, 96129.0% up from the prior year.
  • Net Margin reached 382.1% in Q1 2025 per ORMP's latest filing, up from 3526.44% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 194.81% in Q2 2023 to a low of 3526.44% in Q2 2024.
  • Average Net Margin over 4 years is 1147.36%, with a median of 1035.19% recorded in 2022.
  • Peak YoY movement for Net Margin: soared 136795bps in 2023, then plummeted -333163bps in 2024.
  • A 4-year view of Net Margin shows it stood at 1290.71% in 2022, then skyrocketed by 85bps to 194.81% in 2023, then plummeted by -1710bps to 3526.44% in 2024, then skyrocketed by 89bps to 382.1% in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Net Margin are 382.1% (Q1 2025), 3526.44% (Q2 2024), and 259.12% (Q1 2024).